The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2020

Filed:

Apr. 02, 2018
Applicant:

Eutropics Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

Michael H. Cardone, Dorchester, MA (US);

David J. Richard, Littleton, MA (US);

Assignee:

Eutropics Pharmaceuticals, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/5377 (2006.01); G01N 33/50 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/573 (2006.01); A61K 31/69 (2006.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/5377 (2013.01); A61K 31/573 (2013.01); A61K 31/69 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); G01N 33/5011 (2013.01); G01N 33/5079 (2013.01); G01N 2333/82 (2013.01); G01N 2500/04 (2013.01); G01N 2500/10 (2013.01);
Abstract

The present invention relates to compositions and methods for cancer treatment comprising compounds of Formulae I, II, and III. In some aspects, the invention relates to the treatment of B-cell Lymphoma or other hematopoietic cancers. In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as, for example, B-cell lymphoma, using a combination of one or more compounds of Formulae I, II, and III. Combination therapy with, for example, 26S proteasome inhibitors, such as, for example, Bortezomib, are also included. In another aspect the present invention relates to autoimmune treatment with compounds of Formulae I, II, and III. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.


Find Patent Forward Citations

Loading…